However, the first studies with 153Sm-, 90Y-, 188Re-, and 177Lu-labeled FAP ligands delivered very heterogenous results due to some inherent shortcomings of current FAP ligands such as short tumor retention time and only indirect effect on tumor cells, namely, over CAFs. This evidence concerns the gene FAP and neoplasm.